Bladder cancer: Two chemoradiation therapy regimens on par for muscle-invasive diseaseFebruary 10, 2018Genitourinary Cancer
Adjuvant chemo halves DFS events in upper-tract urothelial cancerFebruary 9, 2018Genitourinary Cancer
Adding docetaxel to hormone therapy for advanced prostate cancer nets QOL benefitFebruary 8, 2018Genitourinary Cancer
Atezolizumab-bevacizumab combo tops sunitinib as first-line therapy for RCCFebruary 7, 2018Renal Cell CarcinomaGenitourinary Cancer
New model predicts survival in atezolizumab-treated advanced urothelial carcinomaFebruary 7, 2018Immuno-oncologyGenitourinary Cancer
Pembrolizumab plus SBRT shows promise for advanced solid tumorsJanuary 27, 2018Immuno-oncologyBreast CancerLung CancerGenitourinary CancerGastroenterologyHead & Neck/Thyroid CancersGynecologic Cancer
OS similar among mRCC patients enrolled in clinical trials across different geographic regionsJanuary 17, 2018Renal Cell CarcinomaGenitourinary Cancer
In Brazil, few patients get second- and third-line treatment for metastatic RCCJanuary 9, 2018Renal Cell CarcinomaGenitourinary Cancer
Mutations linked to checkpoint inhibitor response in RCCJanuary 4, 2018Renal Cell CarcinomaGenitourinary Cancer
DNA vaccine + PD-1 blockade shows promise in mCRPCDecember 9, 2017Immuno-oncologyImmunotherapyGenitourinary Cancer
FDA approves sunitinib malate as adjuvant treatment for RCCNovember 17, 2017Renal Cell CarcinomaGenitourinary Cancer
NCI-MATCH: Nivolumab shows promising activity in noncolorectal cancersNovember 15, 2017Immuno-oncologyGynecologic CancerGenitourinary CancerBreast Cancer
Gut bacteria influenced response to checkpoint inhibitorsNovember 14, 2017Immuno-oncologyMelanomaLung CancerGenitourinary Cancer
